Skip to Content

Apidra Side Effects

Generic Name: insulin glulisine

Note: This document contains side effect information about insulin glulisine. Some of the dosage forms listed on this page may not apply to the brand name Apidra.

For the Consumer

Applies to insulin glulisine: subcutaneous solution

Along with its needed effects, insulin glulisine (the active ingredient contained in Apidra) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking insulin glulisine:

More common
  • Anxiety
  • blurred vision
  • body aches or pain
  • chills
  • cold sweats
  • confusion
  • convulsions
  • cool, pale skin
  • cough
  • depression
  • difficulty with breathing
  • dizziness
  • ear congestion
  • fast heartbeat
  • headache
  • increased hunger
  • loss of voice
  • nasal congestion
  • nightmares
  • runny nose
  • shakiness
  • slurred speech
  • sneezing
  • sore throat
  • unconsciousness
  • unusual tiredness or weakness
Less common
  • Pounding in the ears
  • slow or fast heartbeat
Incidence not known
  • Difficulty with swallowing
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • fast, pounding, or irregular heartbeat or pulse
  • hives
  • increased sweating
  • itching
  • puffiness or swelling of the eyelids or around the eyes, face, lips or tongue
  • skin rash
  • tightness in the chest

Some side effects of insulin glulisine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common
  • Difficulty with moving
  • dry, red, hot, or irritated skin
  • ear congestion
  • loss of voice
  • muscle aches
  • muscle pain or stiffness
  • pain in the joints
Less common
  • Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
  • redistribution or accumulation of body fat

For Healthcare Professionals

Applies to insulin glulisine: subcutaneous solution

General

The most common adverse reactions reported include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, and rash.[Ref]

Metabolic

Common (1% to 10%): Hypoglycemia, hypoglycemic seizure
Frequency not reported: Weight gain[Ref]

Hypersensitivity

In clinical trials of ups to 12 months duration, potential systemic allergic reactions were reported in 4.3% (79 of 1833) patients receiving insulin glulisine (the active ingredient contained in Apidra) compared with 3.8% (58 of 1524) patients receiving comparator short-acting insulins. Permanent discontinuation occurred in 1 patient receiving insulin glulisine.[Ref]

Common (1% to 10%): Local hypersensitivity reactions (redness, swelling, and itching at injection site) Uncommon (0.1% to 1%): Systemic allergic reactions including urticaria, chest tightness, dyspnea, allergic dermatitis, and pruritus
Frequency not reported: Anaphylaxis[Ref]

Local

Among patients using continuous subcutaneous insulin infusion pumps, the rates of catheter occlusions and infusion site reactions were similar with insulin glulisine (the active ingredient contained in Apidra) compared with insulin aspart.[Ref]

Common (1% to 10%): Infusion site reactions
Very rare (less than 0.01%): Catheter occlusions[Ref]

Cardiovascular

Common (1% to 10%): Peripheral edema, hypertension[Ref]

Gastrointestinal

Common (1% to 10%): Diarrhea, pharyngitis, vomiting, nausea[Ref]

Dermatologic

Rare (less than 0.1%): Lipodystrophy[Ref]

Immunologic

Common (1% to 10%): Influenza[Ref]

Respiratory

Common (1% to 10%): Nasopharyngitis, upper respiratory tract infection, sinusitis, bronchitis[Ref]

Musculoskeletal

Common (1% to 10%): Arthralgia, back pain[Ref]

Nervous system

Common (1% to 10%): Headache[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection[Ref]

References

1. Cerner Multum, Inc. "Australian Product Information." O 0

2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

3. "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.

Some side effects of Apidra may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide